产品
编 号：F618285
分子式：C13H13FN2O2S
分子量：280.32
分子式：C13H13FN2O2S
分子量：280.32
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 2409963-83-1
产品详情
生物活性：
LOX-IN-3 is an orally active lysyl oxidase (LOX) inhibitor. LOX-IN-3 can be used for fibrosis, cancer and angiogenesis research.
体内研究：
LOX-IN-3 dihydrochloride monohydrate (Compound 33) (30 mg/kg; orally; once) inhibits lysyl oxidase activity in rats.LOX-IN-3 dihydrochloride monohydrate (10 mg/kg; orally; daily for 14 days) reduces kidney fibrosis in unilateral ureteric obstruction (UUO) mice model.LOX-IN-3 dihydrochloride monohydrate (15 mg/kg; orally; daily for 21 days) reduces lung fibrosis in mice.Animal Model:Male Wistar rats
Dosage:30 mg/kg
Administration:Oral administration, single dose
Result:Completely abolished lysyl oxidase activity. Plasma concentrations of tested compound are far below the IC50 after 8 hours, the half-life of recovery is between 2-3 days (ear) and 24 hours (aorta).
Animal Model:Unilateral ureteric obstruction (UUO) model of acute kidney fibrosis in mice
Dosage:10 mg/kg
Administration:Oral gavage, daily for 14 days
Result:Increased kidney weight and thickness and reduced the area of fibrosis.
Animal Model:C57Bl/6 mice, Bleomycin-induced lung fibrosis model
Dosage:15 mg/kg
Administration:Oral gavage, daily for 21 days
Result:Significantly reduced the Ashcroft score and the lung weight.
体外研究：
LOX-IN-3 dihydrochloride monohydrate (Compound 33) inhibits the bovine LOX and human LOXL2 activities with IC50 values of LOX-IN-3 相关抗体:
LOX-IN-3 is an orally active lysyl oxidase (LOX) inhibitor. LOX-IN-3 can be used for fibrosis, cancer and angiogenesis research.
体内研究：
LOX-IN-3 dihydrochloride monohydrate (Compound 33) (30 mg/kg; orally; once) inhibits lysyl oxidase activity in rats.LOX-IN-3 dihydrochloride monohydrate (10 mg/kg; orally; daily for 14 days) reduces kidney fibrosis in unilateral ureteric obstruction (UUO) mice model.LOX-IN-3 dihydrochloride monohydrate (15 mg/kg; orally; daily for 21 days) reduces lung fibrosis in mice.Animal Model:Male Wistar rats
Dosage:30 mg/kg
Administration:Oral administration, single dose
Result:Completely abolished lysyl oxidase activity. Plasma concentrations of tested compound are far below the IC50 after 8 hours, the half-life of recovery is between 2-3 days (ear) and 24 hours (aorta).
Animal Model:Unilateral ureteric obstruction (UUO) model of acute kidney fibrosis in mice
Dosage:10 mg/kg
Administration:Oral gavage, daily for 14 days
Result:Increased kidney weight and thickness and reduced the area of fibrosis.
Animal Model:C57Bl/6 mice, Bleomycin-induced lung fibrosis model
Dosage:15 mg/kg
Administration:Oral gavage, daily for 21 days
Result:Significantly reduced the Ashcroft score and the lung weight.
体外研究：
LOX-IN-3 dihydrochloride monohydrate (Compound 33) inhibits the bovine LOX and human LOXL2 activities with IC50 values of LOX-IN-3 相关抗体:
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备